Compare SA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | ELVN |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 4.2B |
| IPO Year | 2004 | 2020 |
| Metric | SA | ELVN |
|---|---|---|
| Price | $25.11 | $47.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $59.06 | ★ $74.33 |
| AVG Volume (30 Days) | 519.5K | ★ 1.4M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.26 | $14.79 |
| 52 Week High | $40.06 | $62.32 |
| Indicator | SA | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 53.29 |
| Support Level | $24.01 | $44.18 |
| Resistance Level | $28.01 | $47.88 |
| Average True Range (ATR) | 1.29 | 2.27 |
| MACD | 0.10 | 0.54 |
| Stochastic Oscillator | 35.71 | 48.14 |
Seabridge Gold Inc is a development-stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.